This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX6 or HLX07 Monotherapy in Patients with Metastatic Colorectal Cancer.

Inclusion Criteria:

• Age>=18Y and ≤75Y
• Good Organ Function
• Expected survival time ≥ 3 months
• mCRC that have been diagnosed histologically
• KRAS/NRAS/BRAF WT verified by PCR or NGS of tumor tissue
• ECOG score 0-1;

Exclusion Criteria:

• HIV infection
• Active clinical severe infection;
• A history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.